CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 64 enrolled
Drug / intervention
Oxaliplatindrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00846482
NCT00846482N/ACompleted
CompareCT.gov

Exploratory Study Of The ERCC-1 Gene Expression In Colorectal Cancer Cell Lines And In Patients With Colorectal Cancer

Albert Einstein College of Medicine·interventional·Posted Feb 18, 2009·Updated Sep 16, 2020

In Brief

A clinical study evaluating Oxaliplatin for Colon Cancer and Rectal Cancer. Completed, enrolled 64 participants across 2 sites.

Detailed Summary

This study is for patients with advanced or stage II and III colon or rectal cancer. The primary purpose of this research study is to determine if a particular protein in the patient's blood will change when they receive treatment with a drug called oxaliplatin, which is used to treat the colon or rectal cancer. This protein is called ERCC-1. It is thought that the amount of this protein in the blood could influence the manner in which the patient responds to oxaliplatin.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsColon Cancer, Rectal Cancer
CountriesUnited States
CollaboratorsSanofi

Timeline

N/ACompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedFeb 18, 2009
Enrollment StartFeb 1, 2008
Primary CompletionDec 1, 2018
TodayJul 2, 2026
Enrollment to primary: 10.8 yearsPosted 17.4 years ago

Interventions

Oxaliplatindrug

Oxaliplatin will be administered once every 2 or 3 weeks